Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group Limited has received approval from the U.S. FDA to conduct clinical trials for its new product, JMT206, a recombinant fully human anti-ActRIIA/IIB monoclonal antibody. This product, aimed at weight management for individuals with obesity or overweight and at least one weight-related comorbidity, has shown promising results in preclinical studies, indicating high bioavailability and favorable efficacy and safety profiles.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-based company operating in the pharmaceutical industry. It focuses on developing innovative drugs and therapies, with a market focus on both local and international markets.
Average Trading Volume: 132,699,927
Technical Sentiment Signal: Buy
Current Market Cap: HK$86.16B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.